Source: Annual Congress 2013 –Basic research on lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
H. R. Kim, K. E. Hwang, E. T. Jeong (Iksan, Republic Of Korea). Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin. Eur Respir J 2013; 42: Suppl. 57, 3104

Member's Comments

No comment yet.

Related content which might interest you: Glucocorticoid reduces pemetrexed sensitivity by mediating senescence-associated secretory phenotype in Bcl-2 dependent manner in non-small-cell lung cancer Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015 RBM5 overexpression reverses acquired resistance to gefitinib in PC9/AB2 NSCLC cells Source: International Congress 2016 – Late-breaking translational research in lung cancer Year: 2016 EGFR mutations determine EGFR-MET crosstalk and MET inhibition in lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Lung cancer patients harbouring epidermal growth factor receptor mutation Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer Source: Eur Respir Rev 2010 19: 186-196 Year: 2010 Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Epithelial growth factor receptor (EGFR) mutation status and the treatment of non-small cell lung cancer (NSCLC): A population based quality assurance analysis Source: International Congress 2015 – Quality management in lung cancer Year: 2015 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Epidermal growth factor receptor and related biomarkers evaluated by immunohistochemistry in patients with resected non-small cell lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Noninvasive detection of EGFR T790M mutation in gefitinib resistant non-small cell lung cancer using mutant-enriched PCR Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 The influence of erythropoietin on growth and survival in non-small cell lung cancer cell lines Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006